Coronary and peripheral endothelial functions reflect a status of vascular health and impaired vasomotion is indicative of pathogenesis and prognosis of cardiovascular disease.[1] Testing endothelial function with noninvasive techniques provides an opportunity to evaluate large patient populations with cardiovascular risk factors. Photoplethysmography is one such potentially attractive technique that provides a simple and rapid means for deriving the digital volume pulse (DVP) by measuring the transmission of infrared (IR) light through the finger pulp.[1,2] Chowienczyk et al. demonstrated that albuterol (salbutamol), a β2-agonist, in part of reduces wave refraction by activation of the L-arginine-nitric oxide (NO) pathway and suggested that such a methodology, might be applied for the assessment of endothelial function.[3] Wilkinson et al. described the effects of salbutamol inhalation on the aortic pressure waveform, which correlated with the effect of acetylcholine in the presence of endothelial dysfunction in hypercholesterolemic subjects.[4] Both these studies provide evidence that inhalation of salbutamol is a simple, reliable, noninvasive and reproducible method for assessing endothelial function. In another study, 2.5 mg of nebulized salbutamol was used in postmenopausal, obese women to assess endothelial function. In another study, 2.5 mg of salbutamol by nebulization or 0.25 mg of terbutaline subcutaneously, allowing four days wash-out between each period. Three readings of RI were recorded before and 20, 30 and 15 mins after the administration of β2 agonists respectively in all experiments. The difference in mean RI before and after the administration of β2 agonists was considered for studying the endothelial function as described.[4,6] One-way ANOVA followed by post hoc Bonferroni’s multiple comparison test was used to find out the statistical difference between the three methods of β2-agonist administration.

Decrease in RI from the baseline by both the agonist-salbutamol and terbutaline, suggested normal endothelial function. These findings are in accordance with previous studies involving β2 agonists.[4,6] The mean and standard error (SE) values for the RI indices of the three groups are shown in Table 1. It can be seen that the maximum decrease in RI was obtained with terbutaline, followed by salbutamol inhalation and it was minimum in the salbutamol nebulization method. It has been suggested that a > 6% decrease in RI after administration of β2 agonists is reflects normal endothelial function.[3] In our study, except for salbutamol nebulization, both terbutaline and inhalation of salbutamol produced > 6% decrease in RI. The minimal effect on RI by salbutamol nebulization was associated with marked variability in response as compared to the other two methods. Although terbutaline had the greatest effect on RI, it needs subcutaneous administration by qualified personnel and will be more useful in subjects having respiratory pathology or those who cannot inhale salbutamol properly. On the other hand,

### Table 1

<table>
<thead>
<tr>
<th>Drug treatment</th>
<th>RI (%) Before</th>
<th>RI (%) After</th>
<th>Percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Salbutamol inhalation</td>
<td>71.75 ± 2.46</td>
<td>62.35 ± 2.03</td>
<td>13.71 ± 2.38</td>
</tr>
<tr>
<td>B. Salbutamol nebuliser</td>
<td>70.8 ± 2.08</td>
<td>67.5 ± 3.31</td>
<td>4.49 ± 3.64</td>
</tr>
<tr>
<td>C. Terbutaline subcutaneous</td>
<td>67.3 ± 2.86</td>
<td>56.25 ± 2.69</td>
<td>17.69 ± 3.04</td>
</tr>
</tbody>
</table>

n = 20, Values are expressed as Mean ± SE., F = 4.883; df = (2, 57), P < 0.011 overall, A vs B: P > 0.05; A vs C: P > 0.05; B vs C: P < 0.05
salbutamol inhalation method is found to be reasonably good to study endothelial function. Its administration is simple but is limited in the presence of respiratory problems limiting the absorption from the lungs. In conclusion, inhalation of 400 µg of salbutamol inhalation is a good, simple and noninvasive method for studying endothelial function in a large population.

Madireddy Umamaheshwar Rao Naidu, Yashmaina Sridhar, Pingali Usha Rani, A.A. Mateen
Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad - 500 082, India.
E-mail: mumaidu@yahoo.com

References